This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of Cardiac Compass With OptiVol in the Early Detection of Decompensation Events for Heart Failure (PRECEDE-HF)

This study has been terminated.
(Study enrollment significantly below protocol expectation)
Information provided by:
Medtronic Cardiac Rhythm and Heart Failure Identifier:
First received: July 31, 2007
Last updated: June 8, 2009
Last verified: June 2009
The purpose of the PRECEDE-HF study is to collect data to compare patients whose heart failure is managed using Cardiac Compass with OptiVol (which is a tool in the device that records information about the heart that doctors can use to help treat their heart disease) combined with standard treatment methods (Access Group) to patients whose heart failure is managed by standard treatment methods only (Control Group). This comparison will show if the additional monitoring provided by Cardiac Compass with OptiVol delays the time patients are first admitted to hospital for heart failure or delays the time to death.

Condition Intervention
Congestive Heart Failure Device: Cardiac Compass with OptiVol Fluid Status Monitoring

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: PRECEDE-HF -Prospective, Randomized Evaluation of Cardiac Compass With OptiVol in the Early Detection of Decompensation Events for Heart Failure

Resource links provided by NLM:

Further study details as provided by Medtronic Cardiac Rhythm and Heart Failure:

Primary Outcome Measures:
  • Demonstrate a longer time to first heart failure hospitalization or death in the treatment arm. [ Time Frame: Up to five years ]
  • Demonstrate that the proportion of subjects in the treatment arm experiencing a safety composite event at 6 months is not worse than that in the control arm [ Time Frame: Up to five years ]

Secondary Outcome Measures:
  • Evaluate the combined endpoint of all-cause mortality and cardiovascular hospitalizations. [ Time Frame: Up to five years ]
  • Evaluate a reduction in cardiovascular and HF hospitalizations. [ Time Frame: Up to five years ]

Enrollment: 120
Study Start Date: October 2007
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Standard of Care and Cardiac Compass with OptiVol
Device: Cardiac Compass with OptiVol Fluid Status Monitoring
Review of Cardiac Compass with OptiVol Fluid Status Monitoring
Active Comparator: 2
Standard of Care alone
Device: Cardiac Compass with OptiVol Fluid Status Monitoring
Review of Cardiac Compass with OptiVol Fluid Status Monitoring


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

The following criteria apply to all subjects:

  • Subject has a CRT-D or dual chamber ICD with Cardiac Compass and OptiVol Fluid Status Monitoring implanted in the pectoral region at least 30 days prior to enrollment. CRT-D/ICD must be supported by the Medtronic CareLink Network.
  • Subject has a market-released, transvenous, high voltage RV lead
  • Subject has a market-released RA lead
  • If subject has an LV lead, it must be compatible, not Y-adapted and not currently under investigation
  • Subject's heart failure regimen (i.e. beta blocker and ACE inhibitor (or substitute) unless documented evidence of intolerance is available) adheres to current ACC/AHA guidelines for management of chronic heart failure in adult patients
  • Subject has a history of at least one heart failure related hospitalization, Emergency Department (ED) visit, or urgent visit necessitating IV diuretic, IV inotropic, IV vasodilator, or other parenteral therapy within 12 months prior to baseline evaluation
  • Subject is at least 18 years of age
  • Subject is willing and able to comply with the Clinical Investigation Plan (e.g. willing and able to remain available for follow-up visits, use SentryCheck, etc.)
  • Subject is willing and able to transmit data using the Medtronic CareLink Network
  • Subject (or subject's legally authorized representative) is willing and able to sign and date the study Informed Consent and HIPAA Authorization (U.S.)

Exclusion Criteria

The following criteria apply to all subjects:

  • Subject is post heart transplant or actively listed on the transplant list and reasonable probability (as defined by investigator) of undergoing transplantation in the next year
  • Subject received a coronary artery bypass graft or valve surgery in the last 90 days
  • Subject had a myocardial infarction (MI) in the last 90 days.
  • Subject is indicated for valve replacement/repair
  • Subject's life expectancy due to non-cardiac reasons is less than six months
  • Subject has serum creatinine > 2.5 mg/dL measured within 30 days prior to enrollment.
  • Subject is on chronic renal dialysis
  • Subject is on continuous or intermittent (> 2 stable infusions per week) infusion therapy for HF
  • Subject has complex and uncorrected congenital heart disease
  • Subject is enrolled in a Disease Management Program where an outside vendor, company or service is employed to determine, monitor, and/ or alert a clinician or subject to weight changes or other HF signs or symptoms via interactive or passive systems
  • Subject is implanted with a cardiac hemodynamic monitor or left ventricular assist device(LVAD)
  • Subject is enrolled in a concurrent study, with the exception of a study approved by the Medtronic PRECEDE-HF Clinical Trial Leader prior to enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00510198

  Hide Study Locations
United States, Alaska
Anchorage, Alaska, United States, 99508
United States, Arkansas
Little Rock, Arkansas, United States, 72205
United States, California
Berkeley, California, United States, 94705
Larkspur, California, United States, 94939
United States, Colorado
Colorado Springs, Colorado, United States, 80909
Fort Collins, Colorado, United States, 80528
United States, Florida
Jacksonville, Florida, United States, 32207
United States, Georgia
Atlanta, Georgia, United States, 30306
United States, Illinois
Kankakee, Illinois, United States, 60901
Oak Lawn, Illinois, United States, 60453
Rockford, Illinois, United States, 61107
United States, Indiana
Indianapolis, Indiana, United States, 46260
United States, Kentucky
Louisville, Kentucky, United States, 40205
United States, Louisiana
New Orleans, Louisiana, United States, 70121
United States, Maryland
Takoma Park, Maryland, United States, 20912
United States, Massachusetts
Springfield, Massachusetts, United States, 01199
United States, Michigan
Saginaw, Michigan, United States, 48601
Ypsilanti, Michigan, United States, 48197
United States, Minnesota
St. Cloud, Minnesota, United States, 56303
United States, Missouri
St. Joseph, Missouri, United States, 64501
St. Louis, Missouri, United States, 63110
United States, New York
Albany, New York, United States, 12212
United States, Ohio
Akron, Ohio, United States, 44304
Cleveland, Ohio, United States, 44195
Columbus, Ohio, United States, 43210
Elyria, Ohio, United States, 44035
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73120
United States, Pennsylvania
Doylestown, Pennsylvania, United States, 18901
Lancaster, Pennsylvania, United States, 17603
United States, Tennessee
Nashville, Tennessee, United States, 37205
United States, Texas
Austin, Texas, United States, 78705
United States, Virginia
Richmond, Virginia, United States, 23294
United States, Wisconsin
Milwaukee, Wisconsin, United States, 53215
Sponsors and Collaborators
Medtronic Cardiac Rhythm and Heart Failure
Study Chair: PRECEDE-HF Study Team Medtronic
  More Information

Responsible Party: CRDM Core Clinical, Medtronic CRDM Identifier: NCT00510198     History of Changes
Other Study ID Numbers: 603
Study First Received: July 31, 2007
Last Updated: June 8, 2009

Keywords provided by Medtronic Cardiac Rhythm and Heart Failure:
Heart Disease
Congestive Heart Failure
Thoracic Fluid Monitoring

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases processed this record on August 16, 2017